Floatz logo

Sirolimus

Pulmonary Fibrosis

University of ChicagoSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Pulmonary Fibrosis cohort.

Asset / SponsorPhaseRating
N-Acetyl-L-Cysteine
Boehringer Ingelheim
Phase 3BB
Nintedanib
Boehringer Ingelheim
Phase 3BB
Admilparant
Bristol-Myers Squibb
Phase 3BB
Pirfenidone
Boehringer Ingelheim
Phase 2BB
Sildenafil
Alicia Gerke
Phase 3BB

View all 35 →

Same molecule, other indications

Sirolimus is also rated in:

tuberous sclerosisActive
BBB
Indicative · Phase 3
73 / 100
View asset →
disease related to transplantationDormant
BBB
Indicative · Phase 4
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmActive
BB
Indicative · Phase 2
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →